However, shared mutations of MYB/MYBL1 abnormalities can occur in other low-grade neuroepithelial tumors, including DA (26–41%) (Ramkissoon et al., 2013; Zhang et al., 2013; Qaddoumi et al., 2016), d-OT (8%) (Zhang et al., 2013), IDG (77%), MYBL1 (54%), MYB (23%) (Wefers et al., 2020), and DNET (in one case) (Zhang et al., 2013). Here, MYBL1 is linked to neuroepithelial neoplasm.